
KAUST Develops Deep Learning Tool for Pre-Pregnancy Human Embryo Evaluation
The KAUST scientists demonstrated that deepBlastoid can evaluate images of the models equally well as expert scientists, but 1,000 times faster, SPA reported.
The earliest stages of the human embryo are crucial for understanding fertility, pregnancy complications, and the origins of developmental disorders. However, direct research on human embryos is limited by ethical considerations.
Blastoids are cellular models that represent the embryo at a period known as the blastocyst stage. This stage begins about five days after fertilization and continues until the embryo has implanted itself into the mother's uterine wall (the moment of pregnancy). Importantly, the human blastoids in the KAUST study are composed of stem cells, but not embryonic tissue, and since their discovery in 2021, they have quickly become a preferred human model for scientists to study early embryo development.
In the new study, KAUST researchers trained deepBlastoid on over 2,000 microscopic images of blastoids. Then they used it to assess the effects of chemicals on blastoid development by examining over 10,000 additional images. Understanding how these chemicals can disrupt blastoids has profound implications for women who are taking prescription medicine or other drugs but seek to become pregnant.
"Little is known about the very early stages of embryo development. With deepBlastoid, we can scale up blastoid research to study embryo development and the effects of chemicals on the embryo and pregnancy," said KAUST Associate Professor and member of the KAUST Center of Excellence for Smart Health Mo Li, an expert in stem cell biology and whose lab pioneered embryo models using human blastoids.
He added that deepBlastoid will also help advance reproductive technologies, such as in vitro fertilization.
Generally, scientists evaluate blastoids manually by systematically reviewing a library's worth of images taken under a microscope. This approach not only requires time, but it is also sensitive to the scientist's knowledge and the method used to produce the blastoid, which can vary across laboratories. On the other hand, deepBlastoid can process 273 images per second, offering scientists a tool to assess tens of thousands of blastoids in just a few minutes.
"DeepBlastoid not only matches human performance in accuracy, it delivers an unparalleled increase in throughput. This efficiency allows scientists to analyze vast amounts of data in a short time, enabling experiments that were previously unfeasible," said KAUST Professor and member of the KAUST Center of Excellence for Generative AI Peter Wonka, an expert in deep learning and computer vision and whose research team developed deepBlastoid.
While Li, Wonka, and their colleagues used deepBlastoid to study the blastoid, they noted that by adapting the deep learning algorithm, their approach could be applied to other stem cell models for various embryo stages and organs.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Al Arabiya
4 hours ago
- Al Arabiya
WHO says malnutrition reaching ‘alarming levels' in Gaza
Malnutrition rates are reaching 'alarming levels' in the Gaza Strip, the World Health Organization warned Sunday, saying the 'deliberate blocking' of aid was entirely preventable and had cost many lives. 'Malnutrition is on a dangerous trajectory in the Gaza Strip, marked by a spike in deaths in July,' the WHO said in a statement, adding: 'Most of these people were declared dead on arrival at health facilities or died shortly after, their bodies showing clear signs of severe wasting.'


Argaam
7 hours ago
- Argaam
SPIMACO launches oncology, high-potent drug plant
Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) inaugurated its oncology and high potent drugs plant at a total value of SAR 272 million. In a statement to Tadawul today, July 27, SPIMACO said the plant boasts an annual production capacity exceeding 275 million therapeutic units. Incorporating the latest technologies, the new facility adopts the highest international standards in pharmaceutical manufacturing, ensuring operational efficiency, personnel safety, and environmental sustainability. As all technical, regulatory, and operational requirements were completed, the plant will produce the first commercial batches this month, SPIMACO stated.


Arab News
11 hours ago
- Arab News
Operation to separate Syrian conjoined twins begins in Saudi hospital
RIYADH: A medical team from the Saudi Conjoined Twins Program on Sunday are carrying out an operation to separate Syrian conjoined twin girls in Riyadh. The procedure to separate Celine and Eileen Abdulmunem Al-Shabli is taking place at King Abdullah Specialist Children's Hospital in King Abdulaziz Medical City in Riyadh. Dr. Abdullah Al-Rabeeah, who heads the surgical team and is an advisor at the royal court and supervisor general of Saudi aid agency KSrelief, said the twins come from a Syrian family who sought refuge in Lebanon and had arrived in Saudi Arabia last December. Al-Rabeeah said the mother was pregnant with triplets, two conjoined girls and one healthy, non-conjoined boy. On Feb. 28, 2024, the mother gave birth to the triplets in a caesarean section at Rafik Hariri Hospital in Beirut, he said. The twins are now one year and five months old. Their combined weight is 14 kilograms. He explained that the Syrian conjoined twins arrived from Lebanon to Saudi Arabia on Dec. 29, 2024, in cooperation with the Ministries of Foreign Affairs and Defense. The Saudi medical teams conducted extensive and accurate examinations of the twins ahead of the operation. The operation is expected take about nine hours, and is being carried out in six stages, with the participation of 24 consultants and specialist doctors.